Literature DB >> 21366329

Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure-activity relationship.

Savade Solanki1, Paolo Innocenti, Corine Mas-Droux, Kathy Boxall, Caterina Barillari, Rob L M van Montfort, G Wynne Aherne, Richard Bayliss, Swen Hoelder.   

Abstract

We describe herein the structure-activity relationship (SAR) and cocrystal structures of a series of Nek2 inhibitors derived from the published polo-like kinase 1 (Plk1) inhibitor (R)-1. Our studies reveal a nonlinear SAR for Nek2 and our cocrystal structures show that compounds in this series bind to a DFG-out conformation of Nek2 without extending into the enlarged back pocket commonly found in this conformation. These observations were further investigated, and structure-based design led to Nek2 inhibitors derived from (R)-1 with more than a hundred-fold selectivity against Plk1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366329     DOI: 10.1021/jm1011726

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.

Authors:  C I Wells; N R Kapadia; R M Couñago; D H Drewry
Journal:  Medchemcomm       Date:  2017-12-08       Impact factor: 3.597

Review 2.  CEP proteins: the knights of centrosome dynasty.

Authors:  Ambuj Kumar; Vidya Rajendran; Rao Sethumadhavan; Rituraj Purohit
Journal:  Protoplasma       Date:  2013-02-28       Impact factor: 3.356

3.  A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

Authors:  Mathew P Martin; Jin-Yi Zhu; Harshani R Lawrence; Roberta Pireddu; Yunting Luo; Riazul Alam; Sevil Ozcan; Said M Sebti; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2012-01-27       Impact factor: 5.100

Review 4.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

5.  Discovery of potent NEK2 inhibitors as potential anticancer agents using structure-based exploration of NEK2 pharmacophoric space coupled with QSAR analyses.

Authors:  Mohammad A Khanfar; Fahmy Banat; Shada Alabed; Saja Alqtaishat
Journal:  Mol Divers       Date:  2016-09-06       Impact factor: 2.943

Review 6.  Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.

Authors:  Brendan Frett; Robert V Brown; Mingliang Ma; Wenhao Hu; Haiyong Han; Hong-yu Li
Journal:  J Med Chem       Date:  2014-02-25       Impact factor: 7.446

Review 7.  Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions.

Authors:  Paula Ruiz-Castillo; Stephen L Buchwald
Journal:  Chem Rev       Date:  2016-09-30       Impact factor: 60.622

8.  Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity.

Authors:  Paolo Innocenti; Kwai-Ming J Cheung; Savade Solanki; Corine Mas-Droux; Fiona Rowan; Sharon Yeoh; Kathy Boxall; Maura Westlake; Lisa Pickard; Tara Hardy; Joanne E Baxter; G Wynne Aherne; Richard Bayliss; Andrew M Fry; Swen Hoelder
Journal:  J Med Chem       Date:  2012-03-23       Impact factor: 7.446

9.  Benzimidazole inhibitors of the protein kinase CHK2: clarification of the binding mode by flexible side chain docking and protein-ligand crystallography.

Authors:  Cornelis Matijssen; M Cris Silva-Santisteban; Isaac M Westwood; Samerene Siddique; Vanessa Choi; Peter Sheldrake; Rob L M van Montfort; Julian Blagg
Journal:  Bioorg Med Chem       Date:  2012-09-21       Impact factor: 3.641

Review 10.  On the molecular mechanisms of mitotic kinase activation.

Authors:  Richard Bayliss; Andrew Fry; Tamanna Haq; Sharon Yeoh
Journal:  Open Biol       Date:  2012-11       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.